Have a feature idea you'd love to see implemented?
Let us know!
BLRX Bioline Rx Ltd
Price (delayed)
$0.3233
Market cap
$25.94M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.03
Enterprise value
$17.14M
biolinerx is a clinical-stage, publicly-traded (nasdaq/ tase: blrx) biopharmaceutical development company based in modi'in, israel. this website or social media page (the “site”) of biolinerx ltd. (the “company”) may contain
Highlights
The company's gross profit has surged by 69% QoQ
The revenue has grown by 46% from the previous quarter
Bioline Rx's quick ratio has decreased by 46% YoY but it has increased by 44% QoQ
The equity has contracted by 34% YoY but it has grown by 7% from the previous quarter
The debt has surged by 176% since the previous quarter and by 131% year-on-year
Key stats
What are the main financial stats of BLRX
Market
Valuations
Earnings
Shares outstanding
80.24M
Market cap
$25.94M
Enterprise value
$17.14M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.68
Price to sales (P/S)
1.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.01
Revenue
$17.05M
EBIT
-$27.2M
EBITDA
-$24.9M
Free cash flow
-$30.42M
Per share
Balance sheet
Liquidity
EPS
-$0.03
Free cash flow per share
-$0.38
Book value per share
$0.19
Revenue per share
$0.21
TBVPS
$0.63
Total assets
$64.6M
Total liabilities
$50.62M
Debt
$31.26M
Equity
$13.98M
Working capital
$18.59M
Debt to equity
2.24
Current ratio
1.61
Quick ratio
1.44
Net debt/EBITDA
0.35
Margins
Efficiency
Dividend
EBITDA margin
-146.1%
Gross margin
64.5%
Net margin
-176.7%
Operating margin
-243.5%
Return on assets
-51.7%
Return on equity
-225.6%
Return on invested capital
N/A
Return on capital employed
-79.8%
Return on sales
-159.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BLRX stock price
How has the Bioline Rx stock price performed over time
Intraday
-40.7%
1 week
-29.41%
1 month
-31.36%
1 year
-78.73%
YTD
-79.41%
QTD
-39.69%
Financial performance
How have Bioline Rx's revenue and profit performed over time
Revenue
$17.05M
Gross profit
$11M
Operating income
-$41.52M
Net income
-$30.12M
Gross margin
64.5%
Net margin
-176.7%
The company's gross profit has surged by 69% QoQ
The net margin has surged by 58% since the previous quarter
The revenue has grown by 46% from the previous quarter
BLRX's net income is up by 39% QoQ and by 30% YoY
Growth
What is Bioline Rx's growth rate over time
Valuation
What is Bioline Rx stock price valuation
P/E
N/A
P/B
1.68
P/S
1.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.01
BLRX's EPS is up by 40% since the previous quarter and by 25% year-on-year
The stock's price to book (P/B) is 73% less than its last 4 quarters average of 6.3 and 30% less than its 5-year quarterly average of 2.4
The equity has contracted by 34% YoY but it has grown by 7% from the previous quarter
The revenue has grown by 46% from the previous quarter
Efficiency
How efficient is Bioline Rx business performance
Bioline Rx's return on equity has shrunk by 117% YoY but it has increased by 31% QoQ
BLRX's return on sales has surged by 60% since the previous quarter
BLRX's return on assets is up by 40% since the previous quarter and by 15% year-on-year
Dividends
What is BLRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BLRX.
Financial health
How did Bioline Rx financials performed over time
The company's total assets is 28% higher than its total liabilities
Bioline Rx's quick ratio has decreased by 46% YoY but it has increased by 44% QoQ
The company's current ratio fell by 42% YoY but it rose by 41% QoQ
The debt is 124% greater than the equity
The debt has surged by 176% since the previous quarter and by 131% year-on-year
The debt to equity has soared by 157% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.